% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • fudfighter4 fudfighter4 Jul 1, 2013 4:33 PM Flag

    Tom.berry169 - that $6 billion market cap ...

    Today it became all but a certainty.

    At the current average biotech valuation, 40,000 patients using Arikace would get us there.

    65,000 with CF in the US/Europe for whom Arikace will now be the first-choice antibiotic.

    100,000 with NTM in the US/Europe for whom Arikace will be the only-choice antibiotic - assuming the NTM study (vs placebo) also delivers a significant reduction in bacterial density.

    Today that became far more likely - as did the approval of Arikace for pneumonia / drug-resistant Tuberculosis.

    Thanks for asking :-)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
9.88+0.16(+1.65%)Jun 29 4:00 PMEDT